They did set more hoops, and that was why BGMD abandoned that filing because of the cost involved and had Abbott do the current filing at their cost, no cost to BGMD.
My whole point in this issue was that BGMD had that information within weeks after the first filing in 2012 of the automated version of the gal 3 test and withheld that from shareholders till the 10q filing in November.
Aside from the 80.5pct listed in that filing, They didnt list the remaining 19.5pct which is Aprox. 6,452,000 shares that was in the offering on april 3 2014 and not accounted for in this filing, if they are still held by the buyers of the offering, What does that leave for the public ?????
If I'm not misreading this and those numbers are correct, Theres been a whole lot of consolidation going on here, they're up to something here
DEFINITION OF 'SCHEDULE 13D'
A form that must be filed with the SEC under Rule 13D. The form is required when a person or group acquires more than 5% of any class of a company's shares. This information must be disclosed within 10 days of the transaction. Rule 13D requires the owner to also disclose any other person who has voting power or the power to sell the security.
According to that filing, it seems by the numbers that insiders own 80.5pct if you add them all up,
Jess, this has traded over 70M shares since the April offering, That IMO is a lot of shares, It was a slow takedown so it wouldn't be noticeable, I put this takedown at the feet of the CEO, They may want to take this company private IMO , If that's the case, he don't care about the shareholders
It's true you see 100 share bids and the 200 share ask, but in fact there 5/10/ and 20K sales going thru. This is going nowhere till you hear the status of the 510k filing,What you're seeing now And what you've been seeing all week is Market Maker games of taking the share price down, him buying then raising the price and then him selling, nothing more nothing less, just games.
If the company doesn't come out soon, this will be a total loss IMO This is all on the company to make or break this stock, I think it would be best for the company to put all their cards on the table, Good or bad
Kania works for Flagship Ventures. Not BGMD, Even so Candy , Why sell them ??
It just doesn't make sense If they know the Submission is still active, Why sell ???
If it was for a tax write off it surely doesn't sense, If They would not take the write off and make 3 the the money if it were cleared.
This is beyond bizarre IMO I don't get it
July 2012, we announced the filing of a 510(k) Premarket Notification with the U.S. Food and Drug Administration (FDA) for regulatory clearance for the Abbott ARCHITECT® galectin-3 assay, which is used with Abbott’s fully automated ARCHITECT® immunochemistry instrument platform. In August 2012, Abbott received a letter from the FDA regarding its 510(k) notification that requested additional information and Abbott is undertaking activities to respond to the FDA. In addition, we expect that, in late 2012 or early 2013, Abbott will begin marketing an automated version of the test in the EU under a CE Mark. In May 2012, we submitted a 510(k) to extend the labeling indication for the BGM Galectin-3 test to include individuals in the general adult population who are at risk for developing heart failure based on elevated levels of galectin-3. In July 2012, we received a letter from the FDA regarding our 510(k) notification that requested additional information, including information regarding our clinical validation study and additional analytical study data, and we submitted our response to the FDA in November 2012. If we obtain clearance in the United States for this additional indication, we expect that the potential market for the BGM Galectin-3 test will increase significantly. In May 2012, we also obtained CE Mark in the EU for this expanded indication for the BGM Galectin-3 test.
That may be J, But if you do a little DD, you see the first Automated gal 3 test was kicked back about a month after it was submitted and it wasn't made public till Nov 2012, go look at the filing
Hi J, The FDA Will Only post a clearance, If it does not get cleared , Its up to the company to inform investors, When they didnt get cleared in the last filing , the company released that news in Nov of that year , but they had that info in july.
This is just my opinion, But the buyer of shares in april of this year could have very well shorted the Stock to bring it where it is now, they knew it would take many many months , and if they had to cover they had the 6m shares they bought in april, NOT A BAD GAME HUH !!!
as for taking a long time, the fda cleared version og gal 3 test took 11 months and 10 days to get cleared
Company is silent, Most likely IMO their lawyers told them not to say a word,
My feeling has been for a while the the offering holder with Bgmd blessing to short the stock down to here
If the insiders are the only ones in the know, And they're the only ones selling, That should give you pause. I do know that if they are trading with insider information, You guys are gonna have a great lawsuit.
This looks like it's finished IMO
Dont forget that they IMO " WILL " get the 180 day extension in January 2015, All they have to do is show Nasdaq how they will become compliment, And in that mix they will tell Nasdfaq that at the end of the 180 days if they are NOT compliment, They will do a Reverse Split to become compliment, Most all companys are issued an extension of 180 days.
But I will tell you if they dont get the 180 day extension, RUN FOR THE HILLS IMO
King, don't waste your time and money with your own lawyer, you can be the lead plaintiff in the class action lawsuit to follow if they file